

Supplementary Materials for

Seasonal coronavirus-specific B-cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19 patients

Muriel Aguilar-Bretones^{1*}, Brenda M. Westerhuis^{1*}, Matthijs P. Raadsen¹, Erwin de Bruin¹, Felicity D. Chandler¹, Nisreen M.A. Okba¹, Bart L. Haagmans¹, Thomas Langerak¹, Henrik Endeman², Johannes P.C. van den Akker², Diederik A.M.P.J. Gommers², Eric C.M. van Gorp¹, Corine H. GeurtsvanKessel¹, Rory D. de Vries¹, Ron A.M. Fouchier¹, Barry H.G. Rockx¹, Marion P.G. Koopmans¹ and Gijsbert P. van Nierop^{1†}

***Shared first authorship:** Both authors provided critical contributions and are listed alphabetically by surname.

†Correspondence: Dr. Gijsbert P. van Nierop, Erasmus Medical Center, Wytemaweg 80, 3015CE, Rotterdam, the Netherlands, T: +31107032134, E: g.p.vannierop@erasmusmc.nl


The PDF file includes:

Supplementary Figure 1. Serum IgG titers and IgG B-cell clone reactivity towards N of SARS-CoV and SARS-CoV-2 are strongly correlated.

Supplementary figure 2. Boosted OC43-S_{ECTO} clones recognize epitopes in OC43-S₂.


Supplementary figure 3. Clonal IgG response of a disease control patient towards OC43-, MERS- and SARS2-S_{ECTO}.

Supplementary Table 1. Antigens used in this study and a list of references




Supplementary figure 1. Serum IgG titers and IgG B-cell clone reactivity towards N of SARS-CoV and SARS-CoV-2 are strongly correlated. A) Serum IgG titers against nucleocapsid (N) of SARS-CoV (SARS-N) and SARS-CoV-2 (SARS2-N) were determined using protein microarray (PMA) and ELISA, respectively. Horizontal and vertical dashed lines indicate assay background of PMA and ELISA, respectively. **B)** Culture supernatants of selected SARS-N-reactive IgG B-cell clones were tested for SARS-N and SARS2-N using ELISA. Linear regression shows that both serum IgG titers and B-cell clones significantly correlated. Solid line depicts the best-fit regression coefficient. Dashed line shows the 95% confidence of the best-fit line.

OC43-Secto reactive clones



Supplementary figure 2. Boosted OC43-S_{ecto} clones recognize epitopes in OC43-S₂. A random selection of boosted OC43-S_{ecto} reactive clones that did not show cross-reactivity towards OC43-S₁ (black dots, n=43) were screened using OC43-S and OC43-S₂ on ELISA. Non-reactive clones were included as a negative control (red dots, n=3). The significant correlation suggests all selected boosted OC43-S_{ecto} targeted an epitope within S₂ (linear regression analysis).



Supplementary figure 3. Clonal IgG response of a disease control patient towards OC43-, MERS- and SARS2-S_{ECTO}. B-cells were isolated from PBMC of a disease control patient and stimulated in vitro at limiting dilution to ensure clonal reactivity. Culture supernatants were screened for IgG reactivity towards the ectodomain of spike from HCoV-OC43, MERS-CoV and SARS-CoV-2 to supplement MERS-S_{ECTO} protein microarray results. Three clones that cross-react with MERS-S_{ECTO} were identified.

Supplementary Table 1. Antigens used in this study

Antigen	^a Use	Source or reference	^b Production system	Amino acid residues and ref sequence	^c Tag
229E-N	P	Medix Biochemica (Cat.No: 610091)	E. coli		N-term His-tag
NL63-N	P	Medix Biochemica (Cat.No: 610041)	E. coli		N-term His-tag
HKU1-N	P	Medix Biochemica (Cat.No: 610042)	E. coli		N-term His-tag
OC43-N	P	Medix Biochemica (Cat.No: 610040)	E. coli		N-term His-tag
MERS-N	P	Sino biological (Cat.No: 40068-V08B)	BIC		C-term His-tag
SARS-N	E, P	Sino biological (Cat. No: 40143-V08B)	BIC		C-term His-tag
SARS2-N	E	Sino biological (Cat. No: 40158-V08B)	BIC		C-term His-tag
NL63-S _{ECTO}	P	Kindly provided by Dr. Berend Jan Bosch (1)	DS2	16-1291, UniProt Q6Q1S2	C-term GCN4, Strep-tag
HKU1-S _{ECTO}	P	Kindly provided by Dr. Berend Jan Bosch (2)	HEK293T	14-1266, GenBank HM034837	C-term T4T, mFCS, Strep-tag
OC43-S _{ECTO}	E, P	Kindly provided by Dr. Berend Jan Bosch (3)	HEK293F	15-1263, UniProt Q696P8	C-term GCN4, mFCS, Strep-tag
MERS-S _{ECTO}	P	Kindly provided by Dr. Berend Jan Bosch (2)	BIC	19-1262, GenBank YP_009047204.1	C-term T4T, mFCS, Strep-tag
MERS-S _{ECTO}	E	Sino biological (Cat.No: 40069-V08B)	BIC		C-term His-tag
SARS-S _{ECTO}	P	Kindly provided by Dr. Berend Jan Bosch (4)	HEK293F	1-1160, GenBank AAP13567.1	C-term T4T, mFCS, Strep-tag
SARS2-S _{ECTO}	P	Kindly provided by Dr. Berend Jan Bosch (5)	HEK293T	1-1200, GenBank QHD43416.1	C-term T4T, mFCS, Strep-tag
229E-S ₁	P	Generated in-house (6)	HEK293T	1-537	Mouse Fc-tag
NL63-S ₁	P	Generated in-house (6)	HEK293T	1-717	Mouse Fc-tag
HKU1-S ₁	P	Generated in-house (6)	HEK293T	1-750	Mouse Fc-tag
OC43-S ₁	P	Generated in-house (6)	HEK293T	1-760	Mouse Fc-tag
MERS-S ₁	P	Generated in-house (6)	HEK293T	1-751	Mouse Fc-tag
SARS-S ₁	P	Generated in-house (6)	HEK293T	1-676	Mouse Fc-tag
SARS2-S ₁	P	Generated in-house (6)	HEK293T	1-674	Mouse Fc-tag
SARS2-S _{RBD}	P	Generated in-house (6)	HEK293T	329-538	Mouse Fc-tag
OC43-S ₂	E	Sino biological (40607-V08B1)	BIC		His-tag
HA H1N1(2009)	E	Protein Sciences corporation	BIC		

^aAntigen was used in ELISA (E) or protein microarray (P)

^bAntigen was produced in Escheria coli (E.coli), Drosophila S2 cells (DS2), Baculovirus infected insect cells (BIC), human embryonic kidney cells clone 293 transformed with SV40 T antigen (HEK293T) or Freestyle HEK293 (HEK293F)

^cAntigen contains a transcription factor GCN4 trimerization motif (GCN4), T4 fibrin trimerization motif (T4T), mutated S1/S2 furin cleavage site (mFCS), Histidine-tag (His-tag), Streptavidin-tag (Strep-tag)

References

1. A. C. Walls, M. A. Tortorici, B. Frenz, J. Snijder, W. Li, F. A. Rey, F. DiMaio, B. J. Bosch, D. Velesler, Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. *Nat. Struct. Mol. Biol.* **23**, 899–905 (2016).
2. C. Wang, R. van Haperen, J. Gutiérrez-Álvarez, W. Li, N. M. A. Okba, I. Albuлесcu, I. Widjaja, B. van Dieren, R. Fernandez-Delgado, I. Sola, D. L. Hurdiss, O. Daramola, F. Grosveld, F. J. M. van Kuppeveld, B. L. Haagmans, L. Enjuanes, D. Drabek, B. J. Bosch, Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein. *bioRxiv* (2020), p. 2020.10.20.346916, , doi:10.1101/2020.10.20.346916.
3. I. Widjaja, C. Wang, R. van Haperen, J. Gutiérrez-Álvarez, B. van Dieren, N. M. A. Okba, V. S.

- Raj, W. Li, R. Fernandez-Delgado, F. Grosveld, F. J. M. van Kuppeveld, B. L. Haagmans, L. Enjuanes, D. Drabek, B. J. Bosch, Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. *Emerg. Microbes Infect.* **8**, 516–530 (2019).
4. J. Fedry, D. L. Hurdiss, C. Wang, W. Li, G. Obal, I. Drulyte, S. C. Howes, F. J. M. van Kuppeveld, F. Förster, B. J. Bosch, A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain core. *bioRxiv* (2020), p. 2020.09.30.318261, , doi:10.1101/2020.09.30.318261.
 5. M. Alejandra Tortorici, A. C. Walls, Y. Lang, C. Wang, Z. Li, D. Koerhuis, G. J. Boons, B. J. Bosch, F. A. Rey, R. J. de Groot, D. Velesler, Structural basis for human coronavirus attachment to sialic acid receptors. *Nat. Struct. Mol. Biol.* **26**, 481–489 (2019).
 6. N. M. A. Okba, M. A. Müller, W. Li, C. Wang, C. H. Geurtsvankessel, V. M. Corman, M. M. Lamers, R. S. Sikkema, E. De Bruin, F. D. Chandler, Y. Yazdanpanah, Q. Le Hingrat, D. Descamps, N. Houhou-Fidouh, C. B. E. M. Reusken, B. J. Bosch, C. Drosten, M. P. G. Koopmans, B. L. Haagmans, Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. *Emerg. Infect. Dis.* **26**, 1478–1488 (2020).